Alliance Wealth Advisors LLC UT Purchases New Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Alliance Wealth Advisors LLC UT acquired a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 935 shares of the pharmaceutical company’s stock, valued at approximately $377,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Northwest Investment Counselors LLC acquired a new position in Vertex Pharmaceuticals in the third quarter worth about $25,000. Dunhill Financial LLC lifted its holdings in Vertex Pharmaceuticals by 70.6% during the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 24 shares during the last quarter. Highline Wealth Partners LLC acquired a new position in shares of Vertex Pharmaceuticals in the 3rd quarter worth approximately $27,000. Legacy Investment Solutions LLC bought a new stake in shares of Vertex Pharmaceuticals in the 3rd quarter valued at approximately $33,000. Finally, Truvestments Capital LLC acquired a new stake in shares of Vertex Pharmaceuticals during the 3rd quarter valued at approximately $35,000. Institutional investors own 90.96% of the company’s stock.

Analyst Upgrades and Downgrades

VRTX has been the subject of several recent research reports. BMO Capital Markets lowered their target price on shares of Vertex Pharmaceuticals from $566.00 to $520.00 and set an “outperform” rating for the company in a research note on Friday, December 20th. Wells Fargo & Company downgraded shares of Vertex Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $460.00 price objective for the company. in a research report on Thursday, January 30th. Piper Sandler cut their target price on shares of Vertex Pharmaceuticals from $535.00 to $533.00 and set an “overweight” rating on the stock in a report on Monday, January 27th. Needham & Company LLC reiterated a “hold” rating on shares of Vertex Pharmaceuticals in a research report on Friday, January 31st. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $480.00 price objective on shares of Vertex Pharmaceuticals in a research report on Friday, January 31st. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $502.58.

Vertex Pharmaceuticals Trading Up 2.5 %

Shares of Vertex Pharmaceuticals stock opened at $482.28 on Wednesday. The business has a fifty day simple moving average of $434.73 and a 200-day simple moving average of $462.62. The firm has a market cap of $124.20 billion, a price-to-earnings ratio of -242.35, a price-to-earnings-growth ratio of 2.39 and a beta of 0.41. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $377.85 and a fifty-two week high of $519.88. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.77. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The company had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.69 billion. During the same quarter last year, the firm posted $3.67 EPS. The business’s revenue for the quarter was up 11.6% on a year-over-year basis. On average, equities analysts forecast that Vertex Pharmaceuticals Incorporated will post -1.93 EPS for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.